{"id":"plx-pad","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL3545381","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PLX-PAD consists of placental adherent cells that secrete bioactive factors including cytokines and growth factors that reduce inflammation, promote neovascularization, and enhance tissue healing. The cells work through paracrine signaling to modulate the immune response and stimulate endogenous repair mechanisms in damaged tissues.","oneSentence":"PLX-PAD is a placental-derived cell therapy that promotes tissue repair and regeneration through anti-inflammatory and pro-angiogenic mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:46.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Critical limb ischemia (CLI) / peripheral arterial disease"},{"name":"Acute myocardial infarction (AMI)"}]},"trialDetails":[{"nctId":"NCT04652908","phase":"PHASE1, PHASE2","title":"Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2021-06-21","conditions":"Myelomeningocele","enrollment":55},{"nctId":"NCT06678399","phase":"PHASE1, PHASE2","title":"Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Kelifarma","startDate":"2025-04-01","conditions":"Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery","enrollment":91},{"nctId":"NCT03886506","phase":"","title":"Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization","status":"NO_LONGER_AVAILABLE","sponsor":"Pluristem Ltd.","startDate":"","conditions":"Critical Limb Ischemia (CLI)","enrollment":""},{"nctId":"NCT04389450","phase":"PHASE2","title":"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19","status":"TERMINATED","sponsor":"Pluristem Ltd.","startDate":"2020-10-01","conditions":"COVID, ARDS","enrollment":66},{"nctId":"NCT03006770","phase":"PHASE3","title":"Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization","status":"COMPLETED","sponsor":"Pluristem Ltd.","startDate":"2017-05-22","conditions":"Critical Limb Ischemia (CLI)","enrollment":213},{"nctId":"NCT04614025","phase":"PHASE2","title":"Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19","status":"TERMINATED","sponsor":"Pluristem Ltd.","startDate":"2020-10-19","conditions":"COVID, ARDS","enrollment":23},{"nctId":"NCT03451916","phase":"PHASE3","title":"Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)","status":"COMPLETED","sponsor":"Pluristem Ltd.","startDate":"2018-07-26","conditions":"Hip Fracture","enrollment":240},{"nctId":"NCT05658094","phase":"NA","title":"Exosome Effect on Prevention of Hairloss","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2022-08-01","conditions":"Hair Loss, Alopecia","enrollment":20},{"nctId":"NCT04464213","phase":"PHASE1","title":"Human Placental Mesenchymal Stem Cells Treatment on Diabetic Foot Ulcer","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2020-11-01","conditions":"Diabetic Foot Ulcer","enrollment":43},{"nctId":"NCT01679990","phase":"PHASE2","title":"Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)","status":"COMPLETED","sponsor":"Pluristem Ltd.","startDate":"2012-11-05","conditions":"Intermittent Claudication, Peripheral Artery Disease","enrollment":180},{"nctId":"NCT03746899","phase":"","title":"Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)","status":"AVAILABLE","sponsor":"WideTrial, Inc.","startDate":"","conditions":"Critical Limb Ischemia (CLI)","enrollment":""},{"nctId":"NCT01795950","phase":"PHASE1","title":"Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)","status":"TERMINATED","sponsor":"United Therapeutics","startDate":"2013-04","conditions":"Pulmonary Arterial Hypertension","enrollment":6},{"nctId":"NCT01525667","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Pluristem Ltd.","startDate":"2012-11","conditions":"Total Hip Arthroplasty, Muscle Injury","enrollment":20},{"nctId":"NCT00951210","phase":"PHASE1","title":"Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)","status":"COMPLETED","sponsor":"Pluristem Ltd.","startDate":"2009-08","conditions":"Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia","enrollment":12},{"nctId":"NCT00919958","phase":"PHASE1","title":"Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia","status":"COMPLETED","sponsor":"Pluristem Ltd.","startDate":"2009-06","conditions":"Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["allogeneic Mesenchymal-like Adherent Stromal Cells (ASCs)"],"phase":"phase_3","status":"active","brandName":"PLX-PAD","genericName":"PLX-PAD","companyName":"Pluristem Ltd.","companyId":"pluristem-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"PLX-PAD is a placental-derived cell therapy that promotes tissue repair and regeneration through anti-inflammatory and pro-angiogenic mechanisms. Used for Critical limb ischemia (CLI) / peripheral arterial disease, Acute myocardial infarction (AMI).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":6,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}